Dr Reddy's Labs executes security subscription, shareholders' agreement with TEQ Green Power XI Private Limited, its affiliates
Telangana: Dr. Reddy’s Laboratories Limited has announced that the Company has entered into a Security Subscription and Shareholders’ Agreement for consumption and supply of renewable energy, with TEQ Green Power XI Private Limited and O2 Power SG Pte Ltd, for investment in O2 Renewable Energy IX Private Limited (“SPV”).
The Company and TEQ Green Power XI Private Limited and/or its affiliate will invest in SPV in the ratio of 26:74.
Read also: Dr Reddy's Labs proposed rituximab biosimilar application accepted for review by USFDA, EMA and MHRA
Established in 1984, Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India. The company offers a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddys major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe.
Read also: Dr Reddy's Labs selects Amazon Web Services as preferred cloud provider
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd